Summary
The Ca2+ channel antagonistic potencies of tiamdipine [2-(2-aminoethylthio)methyl-3-carboethoxy-5-carbomethoxy-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine] and nifedipine [2,6-dimethyl-3,5-dicarbomethoxy-4-(2nitrophenyl)-1,4-dihydropyridine] analogs bearing phenyl ring substituents were studied using pharmacologic and radioligand binding techniques. Additionally, analogs of tiamdipine possessing (2-aminoethylthio)methyl-, (2-acetamidoethylthio)methyl-and (2-pyrrolidinylmethylthio)methyl-groups at the C2 position of the 1,4-dihydropyridine ring have been studied.
Tiamdipine and nifedipine analogs inhibited K+-induced contractile responses in rat tail artery. IC50 values of 4-phenyl ring substituted 2-(2-aminoethylthio)methyl tiamdipine analogs ranged from 10−7 mol/l to 10−8 mol/l. However, the corresponding 4-phenyl ring substituted nifedipine analogs covered a wider range of potency from 10−6 mol/l to 10−9 mol/l. K, values of the corresponding tiamdipine analogs for the inhibition of specific [3H]PN 200-110 [( I- ) [3H]isopropyl-4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-3-pyridinecarboxylate] binding-ranged from 10−7 mol/l to 10−9 mol/l in guinea pig ileal and rat heart membranes and rat brain synaptosomes.
The two stereoisomers of tiamdipine and its analog 2-(2acetamidoethylthio)methyl-3-carboethoxy-5-carbomethoxy-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine, and the four stereoisomers of 2-(2-pyrrolidinylmethylthio)methyl-3carboethoxy-5-carbomethoxy-6-methyl-4-(3-nitrophenyl)1,4-dihydropyridine showed high stereoselectivity ratios of approximately (−)/(+) = 100 and 1000 in pharmacologic and binding experiments, respectively.
The inhibitory actions of 2-(2-aminoethylthio)methyltiamdipine analogs against K+-induced contractile responses in rat tail artery developed very slowly requiring at least 2 h for maximum effect. The recoveries of response to K+ depolarization were also correspondingly slow. However, recovery was greatly accelerated by the presence of the 1,4-dihydropyridine activator Bay K 8644 [2,6-dimethyl-3carbomethoxy-5-nitro-4-(2-trifluoromethyl)-1,4-dihydropyridine, 5 × 10−6 mol/l] immediately prior to the K+ challenge. The 2-(2-acetamidoethylthio)methyl tiamdipine derivative and nifedipine produced maximum inhibitory effects within 10 min, and responses recovered rapidly upon washing.
The slow kinetics of onset and offset of action of the tiamdipine analogs and the reduced effects of 4-phenyl substitution relative to agents of the nifedipine series suggest that these two series of 1,4-dihydropyridines exhibit different modes of interaction with the Ca2+ channel. At least part of this difference is to be attributed to the presence of a charged group in the basic tiamdipine series. Trapping of these agents within the membrane phase likely contributes to their observed slow kinetics of action.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arrowsmith JE, Campbell SF, Cross PE, Stubbs JK, Burges RA, Gardiner DG, Blackburn KJ (1986) Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents. J Med Chem 29:1969–1702
Bellemann P, Schade A, Towart R (1983) Dihydropyridine receptor in rat brain labelled with [3H]nimodipine. Proc Natl Acad Sci [USA] 80:2356–2360
Bolger GT, Gengo P, Klockowski R, Luchowski E, Siegel H, Janis RA, Triggle AM, Triggle DJ (1983) Characterization of binding of the Ca2+ channel antagonist, [3H]nitrendipine, to guinea pig ileal smooth muscle. J Pharmacol Exp Ther 225:291–301
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–253
Burges RA, Carter AJ, Gardiner DG, Higgins AJ (1985) Amlodipine, a new dihydropyridine calcium channel blocker with slow onset and long duration of action. Br J Pharmacol 85:281
Burges RA, Gardiner DG, Gwilt M, Higgins AJ, Blackburn KJ, Campbell SF, Cross PE, Stubbs JK (1987) Calcium channel blocking properties of amlodipine in vascular muscle and cardiac muscle in vitro: Evidence for voltage modulation of vascular dihydropyridine receptors. J Cardiovas Pharmacol 9:110–119
Cheng Y, Prusoff WH (1973) Relations between the inhibition constant (KI) and the concentration of an inhibitor that causes a 50% inhibition (ISO) of an enzymatic reaction. Biochem Pharmacol 22:3099–3108
Chester DW, Herbette LG, Mason RP, Joslyn AF, Triggle DJ, Koppel DE (1987) Diffusion of dihydropyridine calcium channel antagonists in cardiac sarcolemmal lipid multibilayers. Biophys J 52:1021–1030
Coburn RA, Wierzba M, Suto MJ, Solo AJ, Triggle AM, Triggle DJ (1988) 1,4-dihydropyridine antagonist activities at the calcium channel: A quantitative structure-activity relationship approach. J Med Chem 31:2103–2107
Faulkner JK, McGibney D (1986) The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. Br J Clin Pharmacol 22:21–25
Fleckenstein A (1983) Calcium antagonism in heart and smooth muscle. John Wiley and Sons, New York
Fossheim R, Joslyn A, Solo AJ, Luchowski E, Rutledge A, Triggle DJ (1988) Crystal structures and pharmacologic activities of 1,4-dihydropyridine calcium channel antagonists of the isobutyl methyl 2,6-dimethyl-4-(substituted phenyl)-1,4-dihydropyridine-3,5-dicarboxylate (nisoldipine) series. J Med Chem 31:300–305
Gandolfi CA, Frigiero M, Spinelli S, Tofanetti O, Tognella S (1988a) Preparation of dihydro(thiomethyl)pyridines as antihypertensives. PCT Int. Appl. WO 8700, 836, Chem Abs 108:217–212
Gandolfi CA, Frigiero M, Riva C, Zalianc A, Passonc A, Germini M, Lumschi B, Tofannetti O (1988b) Tiamdipines: a new class of Ca2+ antagonists. Pharmacol Res Comm 20, suppl II, 174
Gengo P, Su CM, Yousif FB, Triggle DJ (1987) In vitro and in vivo characterization of 2,6-dimethyl-3,5-dicarbomethoxy-4-(2isothiocyano)phenyl-1,4-dihydropyridine as a Ca2+ channel antagonist. Can J Physiol Pharmacol 65:2472–2482
Hajos R (1975) An improved method for the purification of synaptosomal fractions in high purity. Brain Res 93:485–489
Iwanami M, Schibanuma T, Fujimoto M, Kawai R, Tamazawa K, Takenaka T, Takahashi K, Murakami M (1979) Synthesis of new water-soluble dihydropyridine vasodilators. Chem Pharm Bull (Tokyo) 27:1426–1440
Janis RA, Triggle DJ (1984) 1,4-Dihydropyridine Ca2+ channel antagonists and activators: A comparison of binding characteristics with pharmacology. Drug Dev Res 4:257–274
Janis RA, Sarmiento JG, Maurer SC, Bolger GT, Triggle DJ (1984) Characteristics of the binding of [3H]nitrendipine to rabbit ventricular membranes: modification by other Ca2+ channel antagonists and by the Ca2+ channel agonist Bay K 8466. J Pharmacol Exp Ther 231:8–15
Janis RA, Silver PJ, Triggle DJ (1987) Drug action and cellular calcium regulation. Adv Drug Res 16:309–591
Joslyn AF, Luchowski E, Triggle DJ (1988) Dimeric 1,4-dihydropyridines as calcium channel antagonists. J Med Chem 31:1489–1492
Kass R, Arena JP (1988) Tests of the modulated receptor formalism for Ca2+ channel block in heart using amlodipine, a charged 1,4-dihydropyridine. Abstract 46. Calcium antagonists in hypertension, 25th Anniversary International Symposium, Basel, Switzerland, Feb 11–12
Kass RS, Arena JP (1989) Influence of pHO on calcium channel block by amlodipine, a charged dihydropyridine compound: implications for location of the dihydropyridine receptor. J Gen Physiol 93:1109–1127
Kozlowski R, Ehrhard P, Fishli W, Osterrieder W, Holck M (1986) O-Isothiocyanate Dihydropyridine (oNCS-DHP), a long-acting, reversible inhibitor of the Ca+ channel. J Pharmacol Exp Ther 238:1084–1091
Loev B, Goodman MM, Snader KM, Tedesche R, Macko E (1974) “Hantzsch-type” dihydropyridine hypotensive agents. J Med Chem 17:956–965
Mannhold R, Rodenkirchen R, Bayer R (1982) Qualitative and quantitative structure-activity relationships of specific Ca antagonists. Prog Pharmacol 5:25–52
Mason RP, Chester DW, Gonye GE, Herbette LG (1988) The effects of drug charge and membrane structure on the partitioning and location of 1,4-dihydropyridines in model and native lipid bilayers. Biophys J 53:348a
Opie LH (1984) Calcium antagonists and cardiovascular disease. Raven Press, New York
Rampe D, Ferrante J, Triggle DJ (1986) The ontogeny of [3H]-nitrendipine binding sites and 45Ca2+ uptake processes in brain synaptosomes from spontaneously hypertensive rats. Brain Res 394:189–192
Stone PH, Antman EM, Muller JE, Braunwald E (1980) Calcium channel blocking agents in the treatment of cardiovascular disorders. part II: Hemodynamic effects of clinical applications. Ann Intern Med 93:886–904
Tallarida RJ, Murray RB (1981) Manual of pharmacologic calculations, Springer-Verlag, Berlin Heidelberg New York
Towart R, Wehinger E, Meyer H (1981) Effects of unsymmetrical ester substituted 1,4-dihydropyridine derivatives and their optical isomers on contraction of smooth muscle. Naunyn-Schmiedeberg's Arch Pharmacol 317:183–185
Triggle DJ, Janis RA (1987) Calcium channel ligands: Structure and activity. In: Venter JC, Triggle DJ (eds) Structure and physiology of the slow inward calcium channel. Alan R. Liss Inc, New York, pp 29–50
Webb RC, Vanhoutte PM, Bohr DF (1980) Inactivation of released norepinephrine in rat tail artery by neuronal uptake. J Cardiovasc Pharmacol 2:121–132
Webster J, Robb OJ, Jeffers TA, Scott AK, Petrie JC, Towler HM (1987) Once daily amlodipine in the treatment of mild to moderate hypertension. Br J Clin Pharmacol 24:713–719
Wei XY, Luchowski EM, Rutledge A, Su CM, Triggle DJ (1986) Pharmacologic and radioligand binding analysis of the actions of 1,4-dihydropyridine activator-antagonist pairs in smooth muscle. J Pharmacol Exp Ther 239:144–153
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kwon, Y.W., Zhong, Q., Wei, X.Y. et al. The interactions of 1,4-dihydropyridines bearing a 2-(2-aminoethylthio)methyl substituent at voltage-dependent Ca+ channels of smooth muscle, cardiac muscle and neuronal tissues. Naunyn-Schmiedeberg's Arch Pharmacol 341, 128–136 (1990). https://doi.org/10.1007/BF00195069
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00195069